STRO
SUTRO BIOPHARMA, INC.
Key Financials
Net Income
$-191086000
↑ 16.0%
Operating Income
$-158367000
↑ 33.6%
Total Assets
$173.8M
↓ 55.1%
EPS (Diluted)
$-22.49
↓ 659.8%
Revenue
$102.5M
↑ 65.2%
Shareholders' Equity
$-132452000.00
↓ 397.0%
Total Liabilities
$306.3M
↓ 10.6%
Cash & Equivalents
$58.1M
↓ 69.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| SCHEDULE 13G | 7/30/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | STRO |
| Company Name | SUTRO BIOPHARMA, INC. |
| CIK | 1382101 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 650-392-8412 |